Impact of the immunohistochemical panel on patients with breast cancer diagnosis cared for in a referral hospital in the state of Amazonas
Keywords:
prognosis, survival, breast cancer, immunohistochemistry, time-to-treatmentAbstract
Objective: To demonstrate the time between the diagnosis of the disease, the result of the immunohistochemical panel and the beginning of specialized treatment in patients diagnosed with breast cancer seen at the Foundation Center of Oncology of the State of Amazonas, from June to November 2018 and in the same period of 2019. Methods: The study was part retrospective, based on data from medical records, and part prospective, based on data from patients, and we evaluated the time between diagnosis from the immunohistochemical panel and the beginning of specialized treatment in breast cancer patients. Results: 170 patients diagnosed with breast cancer were included, 71 from June to November 2018 and 99 breast cancer patients seen from June to November 2019. The median time between diagnosis and immunohistochemistry results of all patients was 36 days, and comparing the two groups of patients, it was observed that for half of the 2018 patients, the time was less than 105 days, while for half of the 2019 patients, it was less than 27 days. If the times between the result of the immunohistochemical panel and the start of personalized treatment in both groups were compared, it was seen that the median time until the start of treatment was longer for patients in 2018, 94.5 days versus 79 days for patients in 2019. Conclusion: There was a decrease in the time between the diagnosis and the result of the molecular panel in 2019 compared to 2018. Achieving this result more quickly provided the choice of personalized treatment for each patient, having an important impact on survival in that population.
Downloads
References
World Health Organization. International Agency for Research on Cancer. Globocan. Estimated age-standardized incidence rates (World) in 2020, breast, females, all ages [Internet]. Geneva: World Health Organization [cited on Jan 20, 2021]. Available at: https://gco.iarc.fr/today/online-analysis-map?projection=globe
Instituto Nacional de Câncer José Alencar Gomes da Silva. Coordenação de Prevenção e Vigilância. Estatísticas para Câncer de Mama [Internet]. Rio de Janeiro: INCA; 2020 [cited on Jan 20, 2021]. Available at: http://www.oncoguia.org.br/conteudo/estatisticas-para-cancer-de-mama
Vieira SC. Câncer de mama: Consenso da Sociedade Brasileira de Mastologia - Regional Piauí [Internet]. Teresina: EDUFPI, 2017 [cited on Jan 20, 2021]. Available at: https://www.sbmastologia.com.br/medicos
Instituto Nacional do Câncer (INCA). Atlas de Mortalidade por câncer [Internet]. Brasil: INCA [cited on Jan 20, 2021]. Available at: http://mortalidade.inca.gov.br/Mortalidade/prepararModelo05.action
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch Pathol Lab Med. 2020;144(5):545-63. https://doi.org/10.5858/arpa.2019-0904-sa
Weaver O, Leung JWT. Biomarkers and Imaging of Breast Cancer. Am J Roentgenol. 2018;210(2):271-8. https://doi.org/10.2214/ajr.17.18708
Instituto Nacional do Câncer (INCA). Atlas de Mortalidade por câncer [Internet]. Brasil: INCA [cited on Jan 20, 2021]. Available at: http://mortalidade.inca.gov.br/Mortalidade/prepararModelo05.action
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch Pathol Lab Med. 2020;144(5):545-63. https://doi.org/10.5858/arpa.2019-0904-sa
Weaver O, Leung JWT. Biomarkers and Imaging of Breast Cancer. Am J Roentgenol. 2018;210(2):271-8. https://doi.org/10.2214/ajr.17.18708
Huo Q, Cai C, Zhang Y, Kong X, Jiang L, Ma T, et al. Delay in Diagnosis and Treatment of Symptomatic Breast Cancer in China. Ann Surg Oncol. 2015;22(3):883-8. https://doi.org/10.1245/s10434-014-4076-9
Instituto Nacional de Câncer José Alencar Gomes da Silva. Diretrizes para a detecção precoce do câncer de mama no Brasil [Internet]. Rio de Janeiro: INCA; 2015 [cited on Jan 20, 2021]. Available at: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//diretrizes_deteccao_precoce_cancer_mama_brasil.pdf
Brasil. Presidência da República. Lei nº 12.732, de novembro de 2012. Dispõe sobre o primeiro tratamento de pacientes com neoplasia maligna comprovada e estabelece prazo para seu início. Diário Oficial da União [Internet]. 2012 [cited on Jan 20, 2021]. Available at: http://www.planalto.gov.br/ccivil_03/_ato2011-2014/2012/lei/l12732.htm
Farina A, Almeida LLR, Paula LEJ, Medeiros RV, Silva MR, Sommavilla SB. Perfil epidemiológico, clínico, anátomo patológico e imunohistoquímico das pacientes com câncer de mama em Cuiabá (MT). Rev Bras Mastologia. 2017;27(1):74-9. https://doi.org/10.5327/Z201700010017RBM
Dantas GG, Machado DE, Francisco SC, Morais TR, Leite RB, Resende HM, et al. Perfil epidemiológico de pacientes com câncer de mama atendidas em hospital no Sudeste do Brasil: análise de prontuários. Cad UniFOA. 2019;14(41):137-46. https://doi.org/10.47385/cadunifoa.v14i41.2843
Torres DM, Valente PV, Feitosa GP, Matos CFP, Mota FSX, Machado JR. Análise de dados epidemiológicos de pacientes acompanhadas por neoplasia mamária em um hospital de Fortaleza (CE). Rev Bras Mastologia. 2016;26(2):39-44. https://doi.org/10.5327/Z201600020002RBM
Pereira HFBESA. Perfil epidemiológico e clínico de mulheres jovens com câncer de mama no Amazonas: estudo de onze anos [tese online]. Manaus: Universidade Federal do Amazonas; 2016 [cited on Jan 20, 2021]. Available at: https://tede.ufam.edu.br/handle/tede/5818
Raffo CC, Hubie DP, Zanini GL, Aldul-Hak LP, Botogoski SH. Perfil histológico e imuno-histoquímico das pacientes com câncer de mama operadas no Hospital Santa Casa de Curitiba no período de 2014 e 2015. Arq Méd Hosp Fac Cienc Med Santa Casa São Paulo. 2017;62(3):139-45. https://doi.org/10.26432/1809-3019.2017.62.3.139
Monteiro SO. Atrasos no tratamento do câncer de mama: fatores associados em uma coorte de mulheres admitidas em um centro de referência do Rio de Janeiro [dissertação online]. Rio de Janeiro: Escola Nacional de Saúde Pública Sergio Arouca; 2016 [cited on Jan 20, 2021]. Available at: https://www.arca.fiocruz.br/bitstream/icict/20618/2/ve_Sergio_de_Oliveira_ENSP_2016.pdf
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Hilka Flávia Barra Espírito Santo Alves Pereira, Roberto Alves Pereira, Thais Cristina Fonseca da Silva, Henrique Vieira Pereira, Lucas Barbosa Arruda, Valbécia Tavares de Aguiar, Maiara Magri Pereira Olenchi, Moysa Marquez Serruya, Valéria Santos da Costa
This work is licensed under a Creative Commons Attribution 4.0 International License.
